Liver and Biliary Pathology Practice Questions

Q: Fatty liver with hepatomegaly is seen in:

Metabolic syndrome. ***Metabolic syndrome*** - **Metabolic syndrome** is characterized by a cluster of conditions, including **insulin resistance**, obesity, hypertension, and dyslipidemia, which frequently lead to **non-alcoholic fatty liver disease (NAFLD)** and subsequent hepatomegaly [1]. - The accumulation of fat in the liver is a direct consequence of the metabolic derangements, leading to hepatic steatosis, inflammation, and potential fibrosis, with **hepatomegaly** often being a palpable clinical sign [1]. *Marasmus* - **Marasmus** is a form of severe protein-energy malnutrition characterized by significant **weight loss** and muscle wasting, but typically **does not involve fatty liver** or hepatomegaly. - In marasmus, caloric intake is severely deficient, leading to the mobilization of fat stores rather than accumulation in the liver [2]. *Nutmeg liver* - **Nutmeg liver** is a characteristic pathological finding in **congestive hepatopathy**, most often due to **right-sided heart failure**. - It results from chronic passive venous congestion, causing a mottled appearance with alternating areas of congestion and normal parenchyma, but not primarily **fatty infiltration**. *Wilson disease* - **Wilson disease** is a rare genetic disorder of **copper metabolism** that leads to excessive copper accumulation in various organs, including the liver, brain, and eyes. - While it can cause hepatomegaly and liver disease, the primary pathology is copper overload, not **fatty infiltration**, though steatosis can occur secondary to chronic liver injury. *Additional Note* - Enlargement of the liver due to fatty infiltration occurs when triacylglycerol accumulation exceeds the liver's capacity to secrete VLDL, a process seen in conditions like uncontrolled diabetes and certain metabolic stresses [2].

Q: AFP is a tumour marker for which of the following?

HCC. ***Correct Option: HCC*** - **Alpha-fetoprotein (AFP)** is the most widely recognized tumor marker for **Hepatocellular Carcinoma (HCC)**, the most common primary liver cancer [1] - Elevated AFP levels (>400 ng/mL) are highly suggestive of HCC and are used for **diagnosis, monitoring treatment response, and surveillance for recurrence** [1] - AFP is also elevated in **yolk sac tumors** and some **non-seminomatous germ cell tumors**, but HCC remains the primary clinical association [1] *Incorrect: Chordoma* - **Chordomas** are rare malignant bone tumors arising from notochord remnants, typically in the skull base or sacrum - **No specific tumor marker** is routinely used; brachyury (transcription factor) may be used as an immunohistochemical marker for diagnosis - AFP is not associated with chordomas *Incorrect: RCC* - **Renal Cell Carcinoma (RCC)** is the most common kidney malignancy - No highly specific tumor markers exist for RCC; occasionally **elevated LDH, alkaline phosphatase, or calcium** may be seen - AFP is not a marker for RCC *Incorrect: Oncocytoma* - **Renal oncocytoma** is a **benign** renal tumor composed of oncocytes (cells with abundant mitochondria) - Diagnosed primarily by **imaging and histology**, not serum markers - AFP has no role in oncocytoma diagnosis or monitoring **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 399-400.

Q: Intrahepatic cholestasis is seen in -

Haemochromatosis. ***Haemochromatosis*** - **Haemochromatosis** is a hereditary disorder characterized by excessive iron absorption and deposition in multiple organs, including the liver [1]. - Iron accumulation in **hepatocytes** causes direct cellular injury and can lead to **intrahepatic cholestasis** as one of its hepatic manifestations [1]. - The progressive iron overload leads to **hepatic fibrosis** and eventually **cirrhosis**, with cholestatic features often present due to hepatocellular dysfunction [1]. - Clinical presentation includes hepatomegaly, elevated liver enzymes, and signs of chronic liver disease including cholestasis. *Galactosemia* - **Galactosemia** is an inherited metabolic disorder affecting galactose metabolism, leading to accumulation of galactose-1-phosphate. - While it causes significant **hepatocellular damage** and can progress to cirrhosis, the primary hepatic manifestation is **hepatocellular injury** rather than cholestasis. - The liver pathology typically shows fatty infiltration, hepatomegaly, and cirrhosis, but **intrahepatic cholestasis is not a characteristic feature** of galactosemia. *Hypercalcemia* - **Hypercalcemia** does not cause **intrahepatic cholestasis** as a primary manifestation. - Its hepatic effects are minimal and typically related to systemic complications or calcification, not direct cholestatic liver disease. *All of the options* - This option is incorrect because only **haemochromatosis** among these conditions is characteristically associated with intrahepatic cholestasis. - Neither galactosemia nor hypercalcemia typically present with cholestasis as a primary hepatic feature. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 854-855.

Q: What is the primary reason why pre-transfusion testing does not completely eliminate the risk of hepatitis transmission?

Some carriers may not have detectable HBsAg. ***Most carriers do not have HBsAg*** - Some carriers may not have detectable **HBsAg** during the **window period** of acute infection or in **chronic carriers** with very low viral loads [1]. - This creates a gap in screening where infectious individuals can donate blood despite negative **HBsAg** testing, leading to potential transmission [1]. *Present screening test is not sensitive for HBsAg* - Modern **HBsAg screening tests** are highly sensitive and can detect very low levels of the antigen using **enzyme immunoassays** and **chemiluminescent assays**. - The issue is not test sensitivity but rather the **biological absence** of HBsAg during certain phases of hepatitis B infection. *Post transfusions hepatitis is caused by CMV* - **Cytomegalovirus (CMV)** can be transmitted through transfusion but typically causes **mononucleosis-like symptoms** rather than classic hepatitis. - Post-transfusion hepatitis is primarily caused by **hepatitis viruses (B, C)** that specifically target liver cells and cause hepatocellular damage. *HCV not screened* - **Hepatitis C virus (HCV)** is routinely screened in blood donations using **anti-HCV antibody testing** and **nucleic acid testing (NAT)**. - Modern comprehensive screening has dramatically reduced the risk of **HCV transmission** from approximately 1 in 100 to less than 1 in 2 million units. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, p. 838.

Q: Post-hepatic portal hypertension is caused by?

Budd-Chiari Syndrome. ***Budd-Chiari Syndrome*** - **Budd-Chiari Syndrome** is characterized by obstruction of the **hepatic veins** or **inferior vena cava**, leading to blood backing up into the liver and causing **post-hepatic portal hypertension** [1]. - This obstruction prevents proper blood outflow from the liver, increasing pressure in the **hepatic sinusoids** and consequently the **portal venous system** [1]. *Congenital hepatic fibrosis* - This is a **pre-sinusoidal cause** of portal hypertension, often associated with developmental abnormalities of the **bile ducts**. - It leads to increased resistance to blood flow within the **portal tracts** before the sinusoids. *Banti Syndrome* - **Banti Syndrome** is an older term for **splenomegaly** with associated **pancytopenia** and **portal hypertension**, primarily caused by splenic vein thrombosis or increased splenic blood flow. - While it involves portal hypertension, the primary site of obstruction is typically **pre-hepatic** or **intra-hepatic sinusoidal**, not post-hepatic. *Portal vein thrombosis* - **Portal vein thrombosis** causes **pre-hepatic portal hypertension** due to obstruction of the **portal vein** before it enters the liver [2]. - This blockage prevents normal blood flow into the liver, increasing pressure in the **splenic** and **mesenteric venous systems**.

Q: Cholesterol gallstones are made up of:-

Crystalline cholesterol monohydrate. ***Crystalline cholesterol monohydrate*** - **Cholesterol gallstones** primarily consist of **crystalline cholesterol monohydrate**, which forms when the bile becomes supersaturated with cholesterol [1]. - The **crystallization** of cholesterol leads to the formation of visible stones within the gallbladder. *Amorphous cholesterol dihydrate* - This form of cholesterol is not typically found as the primary component of **gallstones**. - **Amorphous** structures lack a defined crystalline lattice and are less stable for forming solid stones. *Amorphous cholesterol monohydrate* - While **cholesterol monohydrate** is the core component, it is in a **crystalline** rather than amorphous state in gallstones [1]. - **Amorphous** forms are generally transient intermediates and do not constitute the bulk of the stones. *Crystalline cholesterol dihydrate* - **Dihydrate** forms of cholesterol are not the main constituent of gallstones; the **monohydrate** form is the predominant type [1]. - The specific hydration state of **cholesterol monohydrate** makes it the primary compound found in the solid, crystalline structure of gallstones [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, p. 882.

Q: Asymptomatic hepatitis B is common in 2-3% of the normal population, but there is increased risk of progression to hepatocellular carcinoma. Why?

Integration of viral DNA with host DNA. ***Integration of viral DNA with host DNA*** - **Hepatitis B virus (HBV)** is a DNA virus that can integrate its DNA into the host hepatocyte genome, leading to **genomic instability** and potentially activating proto-oncogenes or disrupting tumor suppressor genes. - This integration, along with chronic inflammation and repair, is a key mechanism driving the progression to **hepatocellular carcinoma (HCC)** even in asymptomatic carriers. *High rate of proliferation of virus* - While active viral replication (high viral load) is a risk factor for liver damage and HCC, the *rate of proliferation* itself isn't the primary direct cause of carcinogenesis in asymptomatic carriers. - The direct mechanism leading to malignancy is more closely linked to how the virus interacts with the host genome rather than just its abundance. *Inability to induce inflammation to remove the organism* - An inability to clear the virus and a persistent **immune response** actually contribute to chronic inflammation, which is a significant factor in HCC development. However, this is not the most direct reason for the **oncogenic potential** of HBV itself. - While a robust immune response can cause liver damage, the *lack* of one doesn't directly explain the carcinogenic potential; rather, it leads to persistence and chronic disease. *High level of transaminases* - **Elevated transaminase levels** (like ALT and AST) are indicators of hepatocyte damage and inflammation, not a direct cause of liver cancer. - While chronic elevation suggests ongoing liver injury and increased risk, this is a marker of disease activity, not the fundamental mechanism of oncogenesis.

Q: How does liver cirrhosis contribute to the development of edema?

Decreased albumin production. ***Decreased albumin production*** - The **liver** is the primary site of **albumin synthesis** [2]. In cirrhosis, liver damage impairs this synthetic function, leading to **hypoalbuminemia** (low serum albumin). - Albumin is a major contributor to **plasma oncotic pressure**. Reduced oncotic pressure causes fluid to shift from the intravascular space into the interstitial space, resulting in **edema and ascites** [1]. *Increased capillary permeability* - While increased capillary permeability can cause edema, it is **not the primary mechanism** by which liver cirrhosis leads to edema. - Conditions like severe inflammation or sepsis are more commonly associated with widespread increases in capillary permeability. *Increased salt intake* - Although excessive **sodium intake** can worsen edema in patients with cirrhosis, it is **not the fundamental cause** of edema related to the underlying liver disease. - The edema in cirrhosis is primarily due to fluid retention mechanisms driven by liver dysfunction, rather than mere dietary intake. *Increased cardiac output* - In advanced cirrhosis, patients often develop a **hyperdynamic circulatory state** characterized by increased cardiac output and systemic vasodilation. - While this circulatory dysfunction contributes to fluid retention through activation of neurohormonal systems, it is **not the direct cause** of edema as a primary mechanism of fluid extravasation, which is largely driven by decreased oncotic pressure and portal hypertension [3].

Q: A patient with chronic hepatitis B presents with fatigue and abdominal pain. What is the primary mechanism by which hepatitis B increases the risk of hepatocellular carcinoma?

Direct mutagenesis by viral DNA integration. ***Direct mutagenesis by viral DNA integration*** - Hepatitis B virus can integrate its **viral DNA** into the host genome, which may lead to **mutations** and genomic instability in liver cells [1]. - This integration disrupts normal cellular functions and promotes **malignant transformation**, increasing the risk of hepatocellular carcinoma [1]. - The HBx protein is necessary for virus replication and has been implicated in the pathogenesis of hepatocellular carcinoma through transcriptional transactivation of viral and host genes [2]. *Stimulation of liver regeneration* - While chronic inflammation can trigger **liver regeneration**, excessive regeneration itself does not directly cause **carcinogenesis**. - The risk of cancer is related to the **genetic alteration** from viral infection, not merely from the regenerative response. *Inhibition of hepatic cytokine signaling* - This could affect the immune response but does not specifically explain the **increased oncogenic risks** associated with hepatitis B infection. - The mechanism involves direct **viral interactions** rather than mere cytokine modulation. *Immunosuppression leading to secondary infections* - Although immunosuppression can lead to increased susceptibility to infections, it is **not the primary mechanism** of carcinogenesis in chronic hepatitis B. - The risk arises from mutations and abnormal cellular growth due to direct **viral effects**, not just opportunistic infections. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 336-337. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 838-840.

Q: Which microscopic feature is characteristic of primary biliary cholangitis?

Lymphocytic infiltrates and destruction of bile ducts. ***Lymphocytic infiltrates and destruction of bile ducts*** - **Primary biliary cholangitis** is characterized by a **lymphocytic infiltrate** that leads to the destruction of small and medium-sized bile ducts in the portal areas [1]. - This autoimmune response results in **progressive cholestasis** and eventual liver damage [1]. *Noncaseating granulomas* - Noncaseating granulomas are more typical of **sarcoidosis** and **primary sclerosing cholangitis** rather than primary biliary cholangitis. - The presence of **granulomas** does not align with the typical pathology observed in primary biliary cholangitis. *Periductal fibrosis and onion-skinning* - This feature is associated with **primary sclerosing cholangitis**, not primary biliary cholangitis. - In primary biliary cholangitis, lymphocytic infiltrates are more significant than the fibrosis described here. *Fibrosis around bile ducts* - While some fibrosis may be present, it is not a defining feature of primary biliary cholangitis. - The hallmark is the **lymphocytic infiltrates** leading to ductal destruction rather than mere fibrosis around the ducts [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 864-865.

Question 1

Fatty liver with hepatomegaly is seen in:

Accepted Answer

Metabolic syndrome

Answer

Marasmus

Answer

Nutmeg liver

Answer

Wilson disease

Question 2

AFP is a tumour marker for which of the following?

Accepted Answer

HCC

Answer

Chordoma

Answer

RCC

Answer

Oncocytoma

Question 3

Intrahepatic cholestasis is seen in -

Accepted Answer

Haemochromatosis

Answer

Hypercalcemia

Answer

All of the options

Answer

Galactosemia

Question 4

What is the primary reason why pre-transfusion testing does not completely eliminate the risk of hepatitis transmission?

Accepted Answer

Some carriers may not have detectable HBsAg

Answer

Present screening test is not sensitive for HBsAg

Answer

Post transfusions hepatitis is caused by CMV

Answer

HCV not screened

Question 5

Post-hepatic portal hypertension is caused by?

Accepted Answer

Budd-Chiari Syndrome

Answer

Congenital hepatic fibrosis

Answer

Banti Syndrome

Answer

Portal vein thrombosis

Question 6

Cholesterol gallstones are made up of:-

Accepted Answer

Crystalline cholesterol monohydrate

Answer

Amorphous cholesterol dihydrate

Answer

Amorphous cholesterol monohydrate

Answer

Crystalline cholesterol dihydrate

Question 7

Asymptomatic hepatitis B is common in 2-3% of the normal population, but there is increased risk of progression to hepatocellular carcinoma. Why?

Accepted Answer

Integration of viral DNA with host DNA

Answer

High rate of proliferation of virus

Answer

Inability to induce inflammation to remove the organism

Answer

High level of transaminases

Question 8

How does liver cirrhosis contribute to the development of edema?

Accepted Answer

Decreased albumin production

Answer

Increased capillary permeability

Answer

Increased salt intake

Answer

Increased cardiac output

Question 9

A patient with chronic hepatitis B presents with fatigue and abdominal pain. What is the primary mechanism by which hepatitis B increases the risk of hepatocellular carcinoma?

Accepted Answer

Direct mutagenesis by viral DNA integration

Answer

Immunosuppression leading to secondary infections

Answer

Inhibition of hepatic cytokine signaling

Answer

Stimulation of liver regeneration

Question 10

Which microscopic feature is characteristic of primary biliary cholangitis?

Accepted Answer

Lymphocytic infiltrates and destruction of bile ducts

Answer

Fibrosis around bile ducts

Answer

Granulomatous inflammation around bile ducts

Answer

Noncaseating granulomas

Liver and Biliary Pathology — MCQs

Liver and Biliary Pathology — MCQs

On this page

Practice by Chapter

Want unlimited practice?